Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 475 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lung scan Clear all
Terminated No phase listed Observational

Radiation Induced Cardiopulmonary Injury in Humans

NCT02259452
View directory record Official record
Conditions
Thoracic, Pulmonary Injury, Heart Injuries
Interventions
SPECT Lung Perfusion Scan, SPECT Heart Perfusion Scan, Pulmonary Function Tests
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 10, 2026, 5:50 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Investigation of a Novel Oropharyngeal Airway: The ManMaxAirway

NCT03969147
View directory record Official record
Conditions
Airway Obstruction, Respiratory Complication
Interventions
ManMaxAirway oropharyngeal airway adjunct, Guedel Oropharyngeal airway adjunct, No airway adjunct
Device
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Sep 10, 2026, 5:50 AM EDT
Recruiting No phase listed Observational

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

NCT05537922
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Adenocarcinoma
Interventions
Not listed
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Other
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Sep 10, 2026, 5:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy

NCT03331302
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Hyperpolarized Xenon-129 MRI (Experimental), Radioactive Xenon-133 scintigraphy (Active Comparator)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 10, 2026, 5:50 AM EDT
Terminated Phase 1 Interventional

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

NCT00849745
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Nonmyeloablative allogeneic stem cell transplant
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Sep 10, 2026, 5:50 AM EDT
Terminated Phase 3 Interventional Results available

Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism

NCT01458639
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Technegas V SPECT imaging, Xenon-133 Ventilation Planar imaging
Drug
Lead sponsor
Cyclomedica Australia PTY Limited
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Sep 10, 2026, 5:50 AM EDT
Enrolling by invitation No phase listed Observational

Computer Models of Airways in Children and Young Adults With Sleep Apnea and Down Syndrome

NCT01902407
View directory record Official record
Conditions
Down Syndrome, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 90 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 10, 2026, 5:50 AM EDT
Recruiting Phase 3 Interventional

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

NCT03067181
View directory record Official record
Conditions
Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma, Stage I Ovarian Choriocarcinoma, Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage I Testicular Choriocarcinoma AJCC v6 and v7, Stage I Testicular Embryonal Carcinoma AJCC v6 and v7, Stage I Testicular Seminoma AJCC v6 and v7, Stage I Testicular Yolk Sac Tumor AJCC v6 and v7, Stage II Ovarian Choriocarcinoma, Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage II Testicular Choriocarcinoma AJCC v6 and v7, Stage II Testicular Embryonal Carcinoma AJCC v6 and v7, Stage II Testicular Yolk Sac Tumor AJCC v6 and v7, Stage III Ovarian Choriocarcinoma, Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage III Testicular Choriocarcinoma AJCC v6 and v7, Stage III Testicular Embryonal Carcinoma AJCC v6 and v7, Stage III Testicular Yolk Sac Tumor AJCC v6 and v7, Stage IV Ovarian Choriocarcinoma, Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Teratoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Interventions
Best Practice, Biopsy Procedure, Biospecimen Collection, Bleomycin Sulfate, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Pulmonary Function Test, Questionnaire Administration
Other · Procedure · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
1,780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
566
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 338 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 10, 2026, 5:50 AM EDT
Terminated Phase 1 Interventional Results available

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

NCT05035407
View directory record Official record
Conditions
Kita-kyushu Lung Cancer Antigen 1, Human
Interventions
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 10, 2026, 5:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine

NCT06402318
View directory record Official record
Conditions
COVID-19, SARS CoV 2 Virus, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
Interventions
A&M Breathalyzer PROTECT Kiosk
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 10, 2026, 5:50 AM EDT
Not listed No phase listed Observational

Clinical Performance Evaluation of Veye Lung Nodules

NCT04792632
View directory record Official record
Conditions
Lung; Node
Interventions
Veye Lung nodules
Device
Lead sponsor
Aidence
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 10, 2026, 5:50 AM EDT
Completed No phase listed Observational

Early Imaging Biomarkers in NSCLC

NCT03121287
View directory record Official record
Conditions
Thoracic Cancer
Interventions
Imaging Biomarkers, Pulmonary, Imaging, Specimen Collection
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Sep 10, 2026, 5:50 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema

NCT02682147
View directory record Official record
Conditions
Emphysema
Interventions
Sildenafil
Drug
Lead sponsor
Eric A. Hoffman
Other
Eligibility
25 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 10, 2026, 5:50 AM EDT
Completed No phase listed Observational

Addition of microRNA Blood Test to Lung Cancer Screening Low Dose CT

NCT03452514
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Hummingbird Diagnostics
Industry
Eligibility
55 Years to 80 Years
Enrollment
479 participants
Timeline
2017 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 10, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients With Lung Tumors in Close Proximity to the Chest Wall

NCT04507828
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
Treatment Planning using the DIBH Technique
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 10, 2026, 5:50 AM EDT
Not yet recruiting Not applicable Interventional

LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol A

NCT07685028
View directory record Official record
Conditions
Family History of Lung Cancer
Interventions
CT scan, Sybil
Diagnostic Test · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 10, 2026, 5:50 AM EDT
Completed No phase listed Observational

Symptom Burden and Unmet Supportive Care Needs in Lung Cancer Patients Undergoing First or Second Line Immunotherapy

NCT03741868
View directory record Official record
Conditions
Lung Neoplasm
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 10, 2026, 5:50 AM EDT
Terminated Phase 1 Interventional Results available

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

NCT04751383
View directory record Official record
Conditions
High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, Magnetic Resonance Imaging, Magrolimab, Resection
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 10, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

NCT00963807
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Cisplatin, CT, Docetaxel, FDG, FLT, PET/CT, Surgery
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 10, 2026, 5:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

NCT03554473
View directory record Official record
Conditions
Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions
M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 10, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer

NCT00006370
View directory record Official record
Conditions
Breast Cancer, Lung Cancer
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 10, 2026, 5:50 AM EDT
Recruiting No phase listed Observational

Multidimensional Phenotype Classification in Grade 3 Bronchopulmonary Dysplasia

NCT06475976
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Chest computed tomography (CT) with angiography, Bronchoscopy with bronchoalveolar lavage, Echocardiography, 24 hour esophageal pH ("potential of hydrogen") - multichannel intraluminal impedance (MII) monitoring (reflux testing)
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 1 Year
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 10, 2026, 5:50 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Chest Computed Tomography (CT) Screening Study With Antibody Testing

NCT01203579
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Sep 10, 2026, 5:50 AM EDT
Recruiting Phase 4 Interventional

Use of Hyperpolarized 129Xe MR Lung Imaging in Infants

NCT04995562
View directory record Official record
Conditions
Lungs; Developmental Disorder
Interventions
129Xe
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 6 Months
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 10, 2026, 5:50 AM EDT